A second RWD study examined testing for six selected biomarkers (ALK, EGFR, BRAF, ROS-1, PDL-1, KRAS) and targeted treatment patterns among 3,860 advanced non-small lung cancer patients at four OneOncology sites of care. Patients who received all six biomarker tests increased from 13 percent in 2015 to 57 percent in 2020. The study demonstrates a favorable increase in advanced lung cancer biomarker testing over time at OneOncology sites. Among the tested patients, the median time from advanced diagnosis to the first test result was 20 days. And the time from specimen collection after advanced diagnosis to the first test result was 13 days. Of 1,207 patients with a NSCLC with actionable mutations, 390 (32%) received treatment before receiving their test results.
"The insights from this research collaboration will help to inform opportunities to improve care in biomarker testing for patients and to identify best practices in community oncology practices to truly personalize care for patients. For example, shortening the turnaround time of NGS tests may allow more patients who have actionable mutations receive appropriate treatment by reducing the number of patients who will start treatment prior to receiving test results, " said Jamie Freedman, MD, PhD, Head of U.S. Medical Affairs, Genentech. "Furthermore, these real-world studies will prepare us for future research to improve the value of personalized care."
Dr. Schwartzberg is an author on both abstracts. Ari VanderWalde, MD, Medical Director for Precision Oncology at OneOncology and Director of Research at West Cancer Center and Research Institute, is the lead author on both abstracts.
About OneOncology
OneOncology is the national platform for independent community oncology practices working together to improve the lives of everyone living with cancer through a physician-led, data-driven and patient-centric model. OneOncology is comprised of leading community oncology practices representing more than 620 providers practicing at more than 175 sites of care across the United States. To learn more, visit oneoncology.com or LinkedIn.
Back to HCB News
